Cessatech A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.cessatech.com
Clinical Trials
8
Active:3
Completed:4
Trial Phases
2 Phases
Phase 1:5
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (62.5%)Phase 2
3 (37.5%)Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Cessatech A/S
- Target Recruit Count
- 155
- Registration Number
- NCT06364072
- Locations
- 🇪🇸
Hospital General Universitario Dr. Balmis, Alicante, Spain
🇪🇸Hospital Sant Joan de Deu, Barcelona, Spain
🇪🇸Universidad Autonoma de Madrid (UAM) - Hospital Universitario La Paz (HULP) -, Madrid, Spain
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Cessatech A/S
- Target Recruit Count
- 220
- Registration Number
- NCT05508594
- Locations
- 🇩🇰
DanTrials, Copenhagen, NV, Denmark
Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures
Phase 2
Completed
- Conditions
- Analgesia
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Cessatech A/S
- Target Recruit Count
- 25
- Registration Number
- NCT04897750
- Locations
- 🇩🇰
Anæstesi- og Operationsafdelingen 4013 Juliane Marie Centeret, Copenhagen, Region H, Denmark
Study of CT001 in Healthy Volunteers
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Cessatech A/S
- Target Recruit Count
- 14
- Registration Number
- NCT04807335
- Locations
- 🇩🇰
Dantrials, Copenhagen, DK, Denmark
News
No news found